ULive

ULive is a biotechnology company specializing in the development of next-generation live biotherapeutic products (LBPs) derived from the human microbiome. The company leverages a proprietary microbiome engineering platform to identify and optimize specific bacterial strains with therapeutic potential for treating inflammatory, metabolic, and immune-mediated diseases. ULive's approach focuses on restoring microbial balance and modulating host-microbe interactions to address the root causes of chronic conditions. By combining advanced genomic analysis with high-throughput screening, the company aims to deliver precise and effective microbial therapies. ULive is currently advancing several pre-clinical programs targeting high-unmet-need indications in gastroenterology and immunology.